ArticleFrontiers in medicine2025
Global, regional, and national temporal trends in prevalence, deaths and disability-adjusted life years for chronic pulmonary disease, 1990-2021: an age-period-cohort analysis based on the global burden of disease study 2021.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- An Evidence-Informed Clinical Pathway for COPD Exacerbations in Emergency Departments: Diagnostic Assessment, Severity Stratification, and Individualized Management.Journal of clinical medicine · 2026Article
- Diagnostic value of ocular imaging biomarkers in chronic obstructive pulmonary disease: a multicenter prospective cross-sectional study.Journal of thoracic disease · 2026Article
- Burden of chronic obstructive pulmonary disease, related heart failure and risk factors among middle-aged and elderly patients, 1990-2050.Journal of thoracic disease · 2026Article
- Global, regional, and national trends in burden of lung cancer and chronic obstructive pulmonary disease and associated risk factors, 1990-2021: results from the global burden of disease study 2021.NPJ primary care respiratory medicine · 2026Article
- Metabolic stress exacerbates Parkinson's disease pathology through mitochondrial dysfunction and ferroptosis.NPJ Parkinson's disease · 2026Article
- The burden of chronic respiratory disease in Western Pacific Region from 1990 to 2021: a systematic analysis for the global burden of disease study 2021.BMC public health · 2025Article
- The global burden of depression in adolescents and young adults, 1990-2021: systematic analysis of the global burden of disease study.BMC psychiatry · 2025Article
- Epidemiological trends and risk factors of chronic obstructive pulmonary disease in young individuals based on the 2021 global burden of disease data (1990-2021).BMC pulmonary medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality globally, with significant disparities in disease burden across countries and socioeconomic regions. Despite advancements in public health, the global burden of COPD remains substantial, particularly in low- and middle-income countries. This study aims to provide a comprehensive analysis of global, regional, and national trends in COPD-related prevalence, deaths, and disability-adjusted life years (DALYs) from 1990 to 2021 using an age-period-cohort (APC) model. Methods: Data from the Global Burden of Disease Study 2021 were analyzed for 204 countries and territories, stratified by five Sociodemographic Index (SDI) levels. An APC model was employed to assess the temporal effects of age, time periods, and birth cohorts on COPD burden. Trends in prevalence, deaths, and DALYs were evaluated through metrics such as Net Drift, Local Drift, and risk ratios. Results: Globally, from 1990 to 2021, the age-standardized rates of COPD demonstrated a decline of -1.46% (95% UI: -3.36 to 0.39%) in prevalence, -37.12% (95% UI: -43.37% to -27.68%) in deaths, and -36.98% (95% UI: -42.37% to -28.54%) in DALYs. After adjusting for age and cohort effects, the annual changes were -0.35% (95% UI: -0.39% to -0.32%) in prevalence, -3.87% (95% UI: -4.00% to -3.74%) in deaths, and - 2.95% (95% UI: -3.02% to -2.89%) in DALYs. Notably, in middle, low-middle, and low SDI regions, the age-standardized prevalence rates in 2021 showed an increase compared to 1990, with respective changes of 4.03% (95% UI: 2.00-5.89%), 0.13% (95% UI: -2.90 to 2.84%), and 6.71% (95% UI: 4.25-8.91%). However, age-standardized deaths and DALYs significantly decreased across all five SDI regions. From an age effect perspective, globally, over 50% of COPD prevalence is concentrated among individuals aged 65 years and older, particularly in middle, low-middle, and high-middle SDI regions. COPD-related deaths and DALYs have shown a declining trend across all age groups. Globally, the period effect indicates that earlier periods were associated with a higher burden of disease, while cohort effects highlight that birth cohorts around 1920 had a particularly pronounced impact on the COPD burden. Both period and cohort effects exhibited notable heterogeneity across different SDI regions and countries. Conclusion: The prevalence of COPD remains concerning. Compared to 1990, the global prevalence of COPD in 2021 showed a stable or slightly increasing trend, with over half of the countries experiencing an annual increase in prevalence during the 1990-2021 period. Global mortality and DALYs associated with COPD showed a notable decline in 2021 compared to 1990. However, this trend exhibited significant heterogeneity across countries and regions, likely linked to differences in socioeconomic development. Countries in the high-middle and middle SDI regions were found to be more affected by period effects. From an age effect perspective, population aging has undoubtedly exacerbated the COPD burden. Regarding cohort effects, earlier birth cohorts demonstrated a stronger contribution to the increasing disease burden. While Higher levels of socioeconomic development can mitigate the adverse effects associated with earlier birth cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.